Variability in clinical presentation of diabetes mellitus during anti-PD-1 immunotherapy

M Bastin; H Mosbah; A Carlier; A Boudifa; A Villemain; A Hartemann; F Andreelli

doi:10.1016/j.diabet.2019.04.005

Variability in clinical presentation of diabetes mellitus during anti-PD-1 immunotherapy

Diabetes Metab. 2020 Oct;46(5):406-407. doi: 10.1016/j.diabet.2019.04.005. Epub 2019 Apr 26.

Authors

M Bastin¹, H Mosbah¹, A Carlier¹, A Boudifa², A Villemain³, A Hartemann¹, F Andreelli⁴

Affiliations

¹ Diabetology - metabolism department, Sorbonne université, AP-HP, Institut HospitaloUniversitaire de Cardiometabolisme et Nutrition (ICAN), Pitié-Salpêtrière-Charles Foix Hospital, 75013 Paris, France.
² Histocompatibility and immunogenetics department, Sorbonne Université, AP-HP, Pitié-Salpêtrière-Charles Foix Hospital, 75013 Paris, France.
³ Oncology department, Sorbonne Université, AP-HP, Pitié-Salpêtrière-Charles Foix Hospital, 75013 Paris, France.
⁴ Diabetology - metabolism department, Sorbonne université, AP-HP, Institut HospitaloUniversitaire de Cardiometabolisme et Nutrition (ICAN), Pitié-Salpêtrière-Charles Foix Hospital, 75013 Paris, France. Electronic address: fabrizio.andreelli@aphp.fr.

PMID: 31034979
DOI: 10.1016/j.diabet.2019.04.005

No abstract available

Keywords: Diabetes; Diabetic ketoacidosis; Immune-related adverse events; Nivolumab; Non-ketonic hyperosmolar hyperglycaemic state; PD-1 inhibitor.

Publication types

Case Reports
Letter

MeSH terms

Abdominal Pain / physiopathology
Acute Kidney Injury / physiopathology
Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / secondary
Aged
Autoantibodies / metabolism
Confusion / physiopathology
Diabetes Mellitus / chemically induced*
Diabetes Mellitus / drug therapy
Diabetes Mellitus / metabolism
Diabetes Mellitus / physiopathology
Diabetic Ketoacidosis / chemically induced*
Diabetic Ketoacidosis / drug therapy
Diabetic Ketoacidosis / metabolism
Diabetic Ketoacidosis / physiopathology
Female
HLA-DRB1 Chains / genetics
Humans
Hyperglycemic Hyperosmolar Nonketotic Coma / chemically induced*
Hyperglycemic Hyperosmolar Nonketotic Coma / drug therapy
Hyperglycemic Hyperosmolar Nonketotic Coma / metabolism
Hyperglycemic Hyperosmolar Nonketotic Coma / physiopathology
Hypoglycemic Agents / therapeutic use
Immune Checkpoint Inhibitors / adverse effects*
Insulin / therapeutic use
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Male
Middle Aged
Nivolumab / adverse effects*
Polydipsia / physiopathology
Polyuria / physiopathology

Substances

Autoantibodies
HLA-DRB1 Chains
HLA-DRB1*04 antigen
Hypoglycemic Agents
Immune Checkpoint Inhibitors
Insulin
anti-GAD65 autoantibody
Nivolumab